I-Mab and Jiangsu Nhwa collaborate with Biodextris and Ann Romney CND
Category: #health  By Mateen Dalal  Date: 2019-04-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

I-Mab and Jiangsu Nhwa collaborate with Biodextris and Ann Romney CND

The strategic partnership is aimed at jointly developing a new immuno-stimulatory therapy for certain neurologic disorders.

I-Mab Biopharma, a Shanghai-based biotech company, along with the CNS (Central Nervous System) drug development company Jiangsu Nhwa Pharmaceutical, has signed a collaborative research agreement with the world-recognized scientists and clinicians at Biodextris, the biologics contract development & manufacturing organization, and Ann Romney CND (Center for Neurologic Diseases) at Brigham and Women’s Hospital.

Reportedly, the strategic partnership is aimed at jointly developing a new immuno-stimulatory therapy for certain neurologic disorders, with the deployment of the natural power of the immune system. As per the terms of the agreement, the parties are expected to combine their expertise and resources in translational research, basic science, clinical development, manufacturing & commercialization, for speeding up the translation of innovative immunotherapies into the clinic, for some of the most challenging diseases with the greatest unmatched medical needs.

According to a press release issued by I-Mab Biopharma, the Brigham team will be accountable for the preclinical development such as biomarker discovery & validation, and preliminary clinical studies. Biodextris on the other hand, will contribute to CMC development & manufacturing of clinical materials. Sources added that I-Mab and Nhwa will be providing all technical, financial, regulatory and business support for both preclinical and clinical development, along with future commercialization.  

Dr. Zheru Zhang, President, I-Mab, was reportedly quoted saying that the Brigham is globally recognized for its innovation and brilliance in the area of patient care and biomedical research. The latest international collaboration between the industry and a top academic institute is believed to accelerate drug development and scientific advancement as well. He added that I-Mab shares the same goal and has been consistently striving to provide patients around the world with innovative treatments.

Howard L Weiner, Co-director at the Ann Romney Center, said that the advancement of a nasal immune modulator used in vaccines is an exceptional approach towards the treatment of a neurologic disease and moreover, is potent enough to majorly impact the disease prevalence on a global level.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...